The demand for lithium is set to grow 20X by 2040, creating a major opportunity for investors. Elon Musk described it as "like minting money." Enter EnergyX. Their tech can extract 300% more lithium, earning them $100M+ in investments from GM and others.
The Next Gold Rush? - Ad
The demand for lithium is set to grow 20X by 2040, creating a major opportunity for investors. Elon Musk described it as "like minting money." Enter EnergyX. Their tech can extract 300% more lithium, earning them $100M+ in investments from GM and others. More Info ➔ | Disclosure: This is a paid advertisement for EnergyX's Regulation A+ Offering. Please read the offering circular at invest.energyx.com |
|
|
Oil = Monthly Income - Ad
Right now, there's an unusual $25 way to collect MONTHLY income from the oil markets. It's not a stock, bond, or anything you've likely heard about... But it's by far my #1 investment opportunity for 2024. Find out more right now |
|
|
Kamala Harris May Seize This Cutting-Edge Tech -- Act Now - Ad
A new technology (not AI) is powerful enough to save America $1.7 TRILLION in healthcare costs each year. Trump is rumored to use it personally... And Kamala Harris has threatened to have key patents on it seized. Whoever wins the election - it could cause a massive surge in demand... And send a tiny firm with key patents on this technology soaring. It's currently trading for only $7. But it likely won't stay this cheap for long. Get the ticker here before it soars |
|
|
8 Stocks Wall Street Analysts Love Most - Ad
When in doubt over picking which stocks to own it's wise to look at what the experts are saying. Here are the 8 stocks with the highest percentage of buy ratings among analysts on Wall Street today.
|
| | By clicking the link above you will automatically opt-in to receive emails from TechnicalTrading and agree to Privacy Policy |
|
|
|
If You Wait for FDA Approval, It Could Be Too Late ... - Ad
Biotech stocks can be incredibly rewarding, but picking the right ones is nearly impossible without a PhD or insider knowledge. The FDA approval process is long and costly, and 9 out of 10 drugs never make it. However, a special FDA signal has led to stock spikes 97% of the time, regardless of approval. More Info ➔ |
|
|
|